Bariatric surgery-induced weight loss changes immune markers in the endometrium of morbidly obese women

Surgery for Obesity and Related Diseases

Volumn 10, Issue 5, 2014, Pages 921-926

  Linkov, Faina ^a   Elishaev, Esther ^b   Gloyeske, Nika ^c   Edwards, Robert ^a   Althouse, Andrew D ^a   Geller, Melissa A ^d   Svendsen, Charles ^d   Argenta, Peter A ^d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

CD20; CD3; Endometrial cancer prevention; Endometrial hyperplasia; Immunity; Inflammation; Obesity; PTEN

Indexed keywords

BIOLOGICAL MARKER; CD20 ANTIGEN; CD3 ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN;

ADULT; ARTICLE; BARIATRIC SURGERY; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUTEAL PHASE; MAJOR CLINICAL STUDY; MCNEMAR TEST; MENSTRUAL CYCLE; MORBID OBESITY; PATHOLOGIST; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; WEIGHT REDUCTION; ENDOMETRIAL HYPERPLASIA; IMMUNOLOGY; INCIDENTAL FINDING; METABOLISM; MIDDLE AGED; OBESITY, MORBID; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROCEDURES;

ADULT; ANTIGENS, CD20; ANTIGENS, CD3; BARIATRIC SURGERY; BIOLOGICAL MARKERS; ENDOMETRIAL HYPERPLASIA; ENDOMETRIUM; FEMALE; HUMANS; INCIDENTAL FINDINGS; MIDDLE AGED; OBESITY, MORBID; POSTOPERATIVE CARE; PREOPERATIVE CARE; PTEN PHOSPHOHYDROLASE; TISSUE ARRAY ANALYSIS; WEIGHT LOSS;

EID: 84928822873     PISSN: 15507289     EISSN: 18787533     Source Type: Journal    
DOI: 10.1016/j.soard.2014.03.023     Document Type: Article

References (24)

1. Dossus L, Rinaldi S, Becker S., et al. Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. Endocr Relat Cancer 2010; 17:1007-19.
2. Basen-Engquist K, Chang M. Obesity and cancer risk: recent review and evidence. Curr Oncol Rep 2011; 13:71-6.
3. Lewis SJ, Murad A, Chen L., et al. Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. PLoS One 2010; 5:e13485.
4. Hillon P, Guiu B, Vincent J., Petit JM. Obesity, type 2 diabetes and risk of digestive cancer. Gastroenterol Clin Biol 2010; 34: 529-33.
5. Renehan AG, Soerjomataram I, Leitzmann MF. Interpreting the epidemiological evidence linking obesity and cancer: A framework for population-attributable risk estimations in Europe. Eur J Cancer 2010; 46:2581-92.
6. ACS. What are the risk factors of endometrial cancer? 2008; http://www.cancer.org/docroot/CRI/content/CRI-2-4-2X-What-are-the-risk-factors-for-endometrial-cancer.asp. Accessed September 25, 2008.
7. Crosbie EJ, Zwahlen M, Kitchener H.C., Egger M., Renehan AG. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2010; 19: 3119-30.
8. NCI. Endometrial Cancer Key Statistics. 2012; http://www.cancer.org/Cancer/EndometrialCancer/DetailedGuide/endometrial-uterine-cancer-key-statistics. Accessed May 29, 2012.
9. Chia VM, Newcomb PA, Trentham-Dietz A, Hampton JM. Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis. Int J Gynecol Cancer 2007; 17:441-6.
10. Armstrong AJ, Hurd WW, Elguero S, Barker N.M., Zanotti KM. Diagnosis and management of endometrial hyperplasia. J Minim Invasive Gynecol 2012; 19:562-71.
11. Argenta P, Kassing M, Truskinovsky A., Svendsen C. Bariatric surgery and endometrial pathology in asymptomatic morbidly obese women: a prospective, pilot study. BJOG 2012. Dec 12.
12. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol 2012; 30:221-41.
13. Patterson EJ, Urbach DR, Swanstrom LL. A comparison of diet and exercise therapy versus laparoscopic Roux-en-Y gastric bypass surgery for morbid obesity: a decision analysis model. J Am Coll Surg 2003; 196:379-84.
14. Sjostrom L, Gummesson A, Sjostrom C.D., et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 2009; 10:653-62.
15. Mills AM, Longacre TA. Endometrial hyperplasia. Semin Diagn Pathol 2010; 27:199-214.
16. Patsner B. Endometrial cancer in women 45 years of age or younger. Eur J Gynaecol Oncol 2000; 21:249-50.
17. Chiva L, Lapuente F, Gonzalez-Cortijo L, et al. Sparing fertility in young patients with endometrial cancer. Gynecol Oncol Nov 2008; 111:S101-4.
18. Milne K, Kobel M, Kalloger S.E., et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 2009; 4: e6412.
19. Wijayahadi N, Haron MR, Stanslas J, Yusuf Z. Changes in cellular immunity during chemotherapy for primary breast cancer with anthracycline regimens. J Chemother 2007; 19: 716-23.
20. Kormosh N, Laktionov K, Antoshechkina M. Effect of a combination of extract from several plants on cell-mediated and humoral immunity of patients with advanced ovarian cancer. Phytother Res 2006; 20: 424-5.
21. El-Hamarneh T, Hey-Cunningham AJ, Berbic M., Al-Jefout M, Fraser IS, Black K. Cellular immune environment in endometrial polyps. Fertil Steril 2013; 100:1364-72.
22. Berbic M, Ng CH, Black K, et al. A novel pilot study of endometrial stromal cells and immune cell populations in sentinel uterine-draining lymph nodes during the menstrual cycle and in endometriosis. Reprod Sci 2013; 20:1339-48.
23. Balbi G, Napolitano A, Seguino E., et al. The role of hypertension, body mass index, and serum leptin levels in patients with endometrial hyperplasia during premenopausal period. Clin Exp Obstet Gynecol 2012; 39:321-5.
24. Hachisuga T, Fukuda K, Nakamura S., Iwasaka T, Sugimori H. Local immune response in endometrial carcinomas. Br J Obstet Gynaecol 1997; 104:110-4.